Raltegravir is an antiretroviral drug produced by Merck & Co., used to treat HIV infection. It received approval by the U.S. Food and Drug Administration (FDA) on 12 October 2007, the first of a new class of HIV drugs, the integrase inhibitors, to receive such approval. Raltegravir is a Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor. The mechanism of action of raltegravir is as a HIV Integrase Inhibitor. It is grouped under the following drug class(es): HIV-1 Integrase Inhibitors. Its therapeutic use is listed as anti-infectives and antivirals. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Isentress(TM), hydropyrimidine-4-carboxamide, MK-0518 and raltegravirum. Its PubChem CID is 54671008.
Raltegravir
| CAS No | 518048-05-0 |
|---|---|
| Molecular Formula | C20H21FN6O5 |
| Molecular Weight | 444.4 g/mol |
| Synonyms | N-[2-[4-[(4-fluorophenyl)methylcarbamoyl]-5-hydroxy-1-methyl-6-oxopyrimidin-2-yl]propan-2-yl]-5-methyl-1,3,4-oxadiazole-2-carboxamide |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
, used to treat HIV infection. S. Food and Drug Administration (FDA) on 12 October 2007, the first of a new class of HIV drugs, the integrase inhibitors, to receive such approval.
The listed CAS number is 518048-05-0.
The listed molecular formula is C20H21FN6O5.
The listed molecular weight is 444.4 g/mol.
N-[2-[4-[(4-fluorophenyl)methylcarbamoyl]-5-hydroxy-1-methyl-6-oxopyrimidin-2-yl]propan-2-yl]-5-methyl-1,3,4-oxadiazole-2-carboxamide.
The source lists Isentress(TM), hydropyrimidine-4-carboxamide, MK-0518 and raltegravirum.